Zhenyu Yang
86 IP cases indexed. Covers patent matters.
Cases Presided Over
86 cases indexed | Page 3 of 3
Nike, Inc. v.SherryWear, LLC
Nike successfully petitioned to challenge seven claims of SherryWear's patent based on obviousness over prior art references including Spagna and Rose. The Board found a reasonable likelihood of success regarding claim 1, leading to the institution of the IPR.
Nike, Inc. v.SherryWear, LLC
Nike successfully secured institution for all 14 claims of SherryWear's patent, overcoming the Patent Owner's attempt at discretionary denial. The Board found that Nike presented a reasonable likelihood of prevailing on Claim 1 over Barg and Pintor, leading to an IPR trial.
Nike, Inc. v.SherryWear, LLC
Nike successfully petitioned to challenge key claims of SherryWear's intimate apparel patent (9723878) on grounds of obviousness. The PTAB instituted review, finding a reasonable likelihood that at least one claim is unpatentable over combinations of prior art like Vidal/Spagna and Handras/Spagna.
Nike, Inc. v.SherryWear, LLC et al.
Nike successfully petitioned to challenge SherryWear's bra design patent (9808036) on grounds of obviousness over combinations of prior art references. The PTAB institution decision found that Nike had established a reasonable likelihood of prevailing on the asserted claims, leading to trial.
Nike, Inc. v.SherryWear, LLC
Nike successfully petitioned the PTAB to challenge SherryWear's apparel patent, leading the Board to institute proceedings on obviousness grounds. The decision focuses on whether combinations of prior art references teach or suggest the claimed design elements in intimate apparel.
Nike, Inc. v.SherryWear, LLC
Nike challenged SherryWear's claims regarding bra design and intimate apparel based on obviousness over prior art references like Vidal and Pintor. The PTAB institution decision found a reasonable likelihood of prevailing for Nike, specifically regarding independent claim 1 over the combination of Vidal/Pintor, leading to the case being instituted.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
Inari Agriculture successfully petitioned to institute an IPR against Corteva Agriscience's GMO patents based on prior art from Barbour. The Board found a reasonable likelihood of prevailing regarding anticipation and obviousness over the cited publication, moving the case toward trial.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
The PTAB Board upheld the validity of U.S. Patent No. 8,901,378 B2 after finding that the TC1507 germplasm was publicly available prior to the application's filing date. The Board concluded that this availability satisfied priority requirements and prevented Barbour from qualifying as prior art under § 102.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of the PGR petition filed by Inari Agriculture against Pioneer Hi-Bred, finding that the petitioner failed to demonstrate a reasonable expectation of success. The Board specifically rejected obviousness claims because they relied on phenotypic comparisons while ignoring critical genotypic differences in maize breeding technology.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied Inari Agriculture's PGR challenge against Pioneer Hi-Bred International regarding maize breeding claims (1-20). The Board found the petitioner failed to demonstrate unpatentability on grounds of obviousness, utility, or indefiniteness.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
NeoGenomics filed an IPR challenging Natera's prenatal‑testing patent. The parties settled before the Board could institute the trial, and the Board granted a joint motion to terminate the proceeding.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully challenged the '108 patent's claims in a PTAB institution decision, finding reasonable likelihood of prevailing on anticipation for Claim 1. The Board affirmed that prior art disclosure was sufficient to support the enrichment limitation using Meyer et al.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully petitioned IPR against Tecan Genomics' NGS patent (US 10036012), showing a reasonable likelihood that prior art (Meyer) anticipates claims. The Board granted institution, setting the stage for a full trial on all 22 challenged claims.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB issued a final written decision rejecting all grounds of unpatentability asserted by the Petitioner regarding NGS target enrichment claims. The Board adopted the Patent Owner's narrow definition of 'enrichment,' finding that the prior art failed to teach the claimed proportional increase in target fragments.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB upheld the patent against IPR challenges related to NGS target enrichment. The Board clarified that 'enrichment' requires an increased proportion of the sequence relative to others, not just a raw increase in fragment count. Petitioner failed to meet its burden of proof on unpatentability.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of a PGR petition challenging the patentability of an inbred maize variety, finding that the petitioner failed to meet the burden of showing unpatentability on merits. The Board specifically noted the lack of evidence regarding the claimed genotype and found no unsettled legal questions warranting institutional review.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s and Eye Therapies settled their IPR dispute, resulting in a joint motion that terminated the proceedings. The Board granted the termination and kept the settlement confidential.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
The PTAB instituted the IPR petition challenging key claims of a patent related to vasoconstriction agents for eye redness. The Board found that Petitioner demonstrated a reasonable likelihood of prevailing, despite arguments from the Patent Owner regarding prior art limitations and adverse events.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina successfully secured the institution of Inter Partes Review against Molecular Loop Biosciences' patent, challenging claims 1-6 based on anticipation by Gloor and obviousness over multiple prior art references.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina successfully petitioned the PTAB to institute an IPR against Molecular Loop Biosciences regarding next-generation sequencing technology. The Board found a reasonable likelihood of obviousness over Parameswaran and Gloor, allowing the case to proceed to trial.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
The PTAB found all six challenged claims unpatentable due to anticipation and obviousness. The Board determined that the prior art reference Gloor anticipates every claim (1-6). Furthermore, combinations of Parameswaran with other references rendered the remaining claims obvious.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
The PTAB issued a Final Written Decision rejecting the Petitioner's challenge to claims 1-8 of U.S. Patent No. 11041852. The Board adopted the Patent Owner’s narrow construction of 'cross-over error,' limiting it specifically to errors during cluster amplification, and found no anticipation or obviousness over cited prior art.
Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.
Bruker Spatial Biology and 10x Genomics settled their dispute over U.S. Patent 11,542,554, leading the PTAB to terminate the inter partes review. The settlement agreement and related documents were ordered confidential.
Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.
Bruker Spatial Biology successfully petitioned the PTAB to institute an IPR against 10x Genomics, Inc., challenging numerous claims of patent 11542554. The Board found a reasonable likelihood that the challenged claims are unpatentable based on grounds of obviousness (35 U.S.C. § 103).
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy's Laboratories successfully secured institution status for an IPR against Eye Therapies, LLC regarding ophthalmic formulations. The Board found a reasonable likelihood of prevailing on obviousness (35 U.S.C. § 103) based on the combination of prior art references.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.